Apnimed to Participate in Upcoming October Investor Conferences
11 oct. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
10 oct. 2023 08h30 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
02 oct. 2023 08h00 HE
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 sept. 2023 05h30 HE
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
18 sept. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
06 sept. 2023 08h00 HE
|
Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
APNIMED to Participate in Upcoming Investor Conferences in September
30 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
28 août 2023 06h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
01 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
12 juil. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...